WST · Q2 2026 Earnings

Bullish

West Pharmaceutical Services

Reported July 23, 2026

30-second summary

Q2 revenue of $872.3M (+13.8% YoY, +12.7% organic) blew past the $830–850M guide (+$22M vs high end), with adjusted EPS of $2.37 crushing the $2.05–2.12 range (+$0.25 vs high end). Management raised FY2026 revenue guidance by $40M at the midpoint to $3.345–3.380B, lifted FY organic growth another 250bps to 10–11%, and pushed FY adjusted EPS by $0.375 midpoint to $8.85–9.05 — the fifth consecutive guide-raise quarter. Biologics organic +29.2% and HVP Delivery Devices +29.6% did the heavy lifting; the Q3 EPS guide of $2.14–2.24 implies a sequential step-down from Q2's $2.37 despite YoY growth, the one soft spot on an otherwise clean print.

Headline numbers

EPS

Q2 FY2026

$2.37

+13.9% vs est.

Revenue

Q2 FY2026

$0.87B

+13.8% YoY

+3.8% vs est.

Gross margin

Q2 FY2026

37.7%

Free cash flow

Q2 FY2026

$0.13B

Operating margin

Q2 FY2026

20.5%

Key financials

Q2 FY2026

Metric	Q2 FY2026	Q2 FY2025	YoY	Q1 FY2026	QoQ
Revenue	$0.87B	$0.77B	+13.8%	$0.84B	+3.2%
EPS	$2.37	$1.84	+28.8%	$2.13	+11.3%
Gross margin	37.7%	35.7%	+200bps	35.1%	+260bps
Operating margin	20.5%	20.1%	+40bps	21.0%	-50bps
Free cash flow	$0.13B	—	—	$0.05B	+171.2%

Guidance

Company raised full-year FY2026 revenue and EPS guidance following a strong Q2 beat on both revenue and earnings; organic growth guidance lifted 300+ bps.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q2 FY2026	$830M to $850M	$872.3M	+$22.3M to $42.3M above guide; +3.8% surprise vs. consensus	Beat
Organic Revenue Growth	Q2 FY2026	7.0% to 9.6%	12.7%	+3.1 to +5.7 pts above guide	Beat
Adjusted EPS (non-GAAP)	Q2 FY2026	$2.05 to $2.12	$2.37	+$0.25 to $0.32 above guide; +13.9% surprise vs. consensus	Beat

New guidance

Metric	Period	Guide	YoY
Revenue	Q3 FY2026	$820M to $835M	+2.5% to +4.4% YoY
Reported Revenue Growth	Q3 FY2026	1.9% to 3.8%	—
Organic Revenue Growth	Q3 FY2026	7.0% to 8.9%	—
Adjusted EPS (non-GAAP)	Q3 FY2026	$2.14 to $2.24	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2026	$3.295B to $3.350B	$3.345B to $3.380B	+$50M to $85M (midpoint +$35M)	Raised
Reported Revenue Growth	FY2026	7.2% to 9.0%	8.8% to 10.0%	+1.6 to +2.8 pts	Raised
Organic Revenue Growth	FY2026	7.0% to 9.0%	10.0% to 11.0%	+3.0 to +4.0 pts	Raised
Adjusted EPS (non-GAAP)	FY2026	$8.40 to $8.75	$8.85 to $9.05	+$0.45 to $0.65 (midpoint +$0.375)	Raised

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Proprietary Products	$0.723B	$0.62B	+16.6%
High-Value Product Components	$0.424B	—	+19.4%
HVP Delivery Devices	$0.131B	$0.1B	+31.7%
Standard Products	$0.167B	$0.161B	+4.0%
West Vantage	$0.15B	—	+2.0%
Biologics	$0.375B	—	+30.3%
Pharma	$0.205B	—	+3.3%
Generics	$0.143B	—	+6.9%

Other KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Americas	$0.389B	—	+11.2%
Europe, Middle East, Africa	$0.4B	—	+14.3%
Asia Pacific	$0.084B	—	+24.9%
Organic Net Sales Growth	12.7%	—	—
Adjusted Operating Margin	22.6%	—	—
Operating Cash Flow	$213.9M	—	—
Capital Expenditures	$85.9M	—	—
HVP Components % of Total Sales	49%	—	—
HVP Delivery Devices % of Total Sales	15%	—	—
West Vantage % of Total Sales	17%	—	—
Share Repurchases (H1 2026)	1.8M shares at $258.03	—	—

Management tone

Transcript not available for this quarter; tone analysis skipped. Prepared-remarks framing sourced from press release quotes only.

Narrative arc: Customer destocking → Transition year retired → Conservative FY start → Demand outpaces supply globally → Structural mix shift compounding.

The press release language ("net sales and adjusted EPS exceeding our expectations", "continued strength in Biologics", "favorable mix shift from HVP upgrades including Annex 1", "ongoing growth in GLP-1 elastomers") mirrors the Q1 posture almost verbatim, which itself is a signal — management is not adding hedges. The FY organic growth guide moving from 7–9% to 10–11% after one additional quarter of data is the strongest expression of confidence available inside the release format: a 250bps mid-year lift to organic growth guidance is unusual for a business that historically framed itself as measured.

The Q3 EPS guide of $2.14–2.24 is the one dissonant note relative to the beat-and-raise pattern. In absolute terms the guide sits well below Q2's $2.37 print, and the FY2026 EPS raise ($8.85–9.05 midpoint $8.95) minus H1 actuals of $4.50 (Q1 $2.13 + Q2 $2.37) leaves $4.45 for H2 — meaning Q4 is guided implicitly to $2.21–2.31, roughly in line with Q3. Sequential margin acceleration is embedded in the guide, but the H2 EPS is not stepping up materially from H1 despite the "materially better" H2 margin commentary from Q1.

Answers to last quarter's watch list

Q2 FY2026 organic growth landing in the upper half of the 7.0%–9.6% guide. Organic growth of 12.7% printed 310bps above the high end of the guide, more than validating the "conservative" framing. The FY organic guide has now been raised another 250bps to 10–11%, meaning Q1 was not a pull-forward — Q2 confirmed the FY setup is itself still conservative. Status: Resolved positively

HVP Components organic growth holding ≥15% in Q2. HVP Components grew +19.4% reported (+18.4% organic) in Q2, sustaining the acceleration and running well above the FY "low double digits" framing. Status: Resolved positively

First clean disclosure of HVP Delivery Devices ex-SmartDose run-rate. No pro-forma ex-SmartDose disclosure appeared in the press release. HVP Delivery Devices printed +29.6% reported with SmartDose 3.5mL still in the base; the AbbVie close was not confirmed as completed. Status: Continue monitoring

Adjusted operating margin holding above 21% sequentially. Adjusted operating margin of 22.6% expanded 230bps YoY and 120bps sequentially from Q1's 21.4%, well above the sustain threshold. Q2 alone effectively delivered the FY ">100bps expansion" target. Status: Resolved positively

FY2026 GLP-1 revenue mix update. The press release referenced "ongoing growth in GLP-1 elastomers" qualitatively but did not refresh the combined GLP-1 disclosure. The 250bps FY organic raise cannot be cleanly attributed between GLP-1 and non-GLP-1 without transcript detail. Status: Continue monitoring

Capex cadence relative to the $250–275M FY range. H1 capex disclosed at $85.9M cumulative, tracking below the $125–137M H1 run-rate implied by the unchanged $250–275M FY range. FCF normalization on the capex side is on track. Status: Resolved neutrally

What to watch into next quarter

Q3 organic growth landing above the 7.0–8.9% guide. The pattern of beating guides by 300+bps is now two quarters deep. A Q3 print inside the guided range would signal the conservatism buffer has narrowed; a print above 10% would force a third FY raise.

Q3 EPS resolving the implied sequential step-down. The $2.14–2.24 guide represents a sequential decline from Q2's $2.37 — watch whether the actual print restores the beat pattern or confirms real H2 EPS moderation.

First disclosure of HVP Delivery Devices post-SmartDose divestiture. The AbbVie close was flagged as mid-2026; Q3 should be the first quarter with a clean pro-forma base, and management should quantify the residual delivery-device run-rate.

Adjusted operating margin sustaining above 22% into H2. Q2's 22.6% is the highest quarterly print in the trajectory shown; sequential compression back below 22% in Q3 would undermine the "H2 materially better than H1" framing carried over from Q1.

Biologics end-market growth holding above 25%. Two consecutive quarters above 30% raises the bar; deceleration toward 15–20% would signal the mix-shift tailwind is peaking rather than compounding.

GLP-1 revenue mix refresh alongside Q3 print. A refresh would allow reconciliation of how much of the two-quarter FY raise is GLP-1 driven versus broader biologics/Annex 1 mix.

Sources

West Pharmaceutical Services Q2 2026 Earnings Release (SEC EDGAR): https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/exh991q22026earningsrelease.htm
Tapebrief Q1 2026, Q4 2025, Q3 2025, Q2 2025 WST briefs (referenced for prior-quarter guidance trajectory, watch list, and multi-quarter EPS raise cadence)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.